PromarkerD's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for PromarkerD. Showing past 6 months and next 12 months · 4 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| PromarkerD | Proteomics International Laboratories Ltd | Diagnostic Device | Approved | 0 | ||||
| DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study | Amsterdam UMC, location VUmc | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy | Sichuan Academy of Medical Sciences | — | Phase 4 | — | — | — | — | — |
| Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study | Steno Diabetes Center Copenhagen | — | Phase 4 | — | — | — | — | — |
| Mechanism of SGLT2 Inhibition in the Kidney | University of Michigan | — | Phase 4 | — | — | — | — | — |
| Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | University of Aarhus | — | Phase 4 | — | — | — | — | — |
| PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Brigham and Women's Hospital | — | Phase 4 | — | — | — | — | — |
| Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients | Daewoong Pharmaceutical Co. LTD. | — | Phase 3 | — | — | — | — | — |
| "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes" | Chittagong Medical College | — | Phase 3 | — | — | — | — | — |
| Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy | Second Affiliated Hospital, School of Medicine, Zhejiang University | — | PHASE2/PHASE3 | — | — | — | — | — |
| Atrasentan in Patients With Proteinuric Glomerular Diseases | Novartis Pharmaceuticals | — | Phase 2 | — | — | — | — | — |
| Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) | Shinshu University | — | Phase 2 | — | — | — | — | — |
| NAD Augmentation in Diabetes Kidney Disease | Brigham and Women's Hospital | — | Phase 2 | — | — | — | — | — |
| Renal Mechanism of SGLT2 Inhibition | University of Colorado, Denver | — | Phase 2 | — | — | — | — | — |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | Regeneron Pharmaceuticals | — | Phase 2 | — | — | — | — | — |
| dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation | University Medical Center Groningen | — | Phase 2 | — | — | — | — | — |
| Reducing Risk of Diabetic Ketoacidosis in Type 1 Diabetes and Kidney Disease Using Continuous Ketone Monitoring | HealthPartners Institute | — | Phase 2 | — | — | — | — | — |
| Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease | PT. JES Kasih Nusantara Sejahterah | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial | PT. Prodia Stem Cell Indonesia | — | PHASE1/PHASE2 | — | — | — | — | — |